Free Trial

Check-Cap Q4 2022 Earnings Report

Check-Cap logo
$0.76 -0.01 (-1.47%)
As of 02/21/2025 03:46 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Check-Cap EPS Results

Actual EPS
-$0.64
Consensus EPS
-$0.68
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Check-Cap Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Check-Cap Announcement Details

Quarter
Q4 2022
Time
N/A

Conference Call Resources

Check-Cap Earnings Headlines

Elon Takes Aim at Social Security
Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social Security, finding what he says is widespread fraud across the agency.
See More Check-Cap Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Check-Cap? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Check-Cap and other key companies, straight to your email.

About Check-Cap

Check-Cap (NASDAQ:CHEK), a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.

View Check-Cap Profile

More Earnings Resources from MarketBeat